110 related articles for article (PubMed ID: 25285953)
1. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection.
Jain A; Constantinescu S; Maloo M; Mukerji AN; Karachristos A; Lau K; Di Carlo A
Transplantation; 2014 Oct; 98(7):e68-70. PubMed ID: 25285953
[No Abstract] [Full Text] [Related]
2. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction.
Jain A; Sharma R; Ryan C; Tsoulfas G; Orloff M; Abt P; Kashyap R; Batzold P; Sauberman L; Safadjou S; Graham M; Bozorgzadeh A
Liver Transpl; 2008 Feb; 14(2):202-9. PubMed ID: 18236395
[TBL] [Abstract][Full Text] [Related]
3. Intravenous mycophenolate mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation.
Jain A; Mohanka R; Orloff M; Abt P; Kashyap R; Kelley M; Burlee K; Bozorgzadeh A
Exp Clin Transplant; 2005 Dec; 3(2):361-5. PubMed ID: 16417444
[TBL] [Abstract][Full Text] [Related]
4. Reversal of chronic rejection after treatment failure with FK506 and RS61443.
Roberts JP; Lake JR; Hebert M; Nikolai B; Ascher NL; Ferrell LD
Transplantation; 1993 Oct; 56(4):1021-3. PubMed ID: 7692634
[No Abstract] [Full Text] [Related]
5. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
[TBL] [Abstract][Full Text] [Related]
8. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient.
Dopazo C; Bilbao I; Lázaro JL; Sapisochin G; Caralt M; Blanco L; Castells L; Charco R
Transplant Proc; 2009 Apr; 41(3):1021-4. PubMed ID: 19376416
[TBL] [Abstract][Full Text] [Related]
9. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil monotherapy in liver transplantation.
Pierini A; Mirabella S; Brunati A; Ricchiuti A; Franchello A; Salizzoni M
Transplant Proc; 2005; 37(6):2614-5. PubMed ID: 16182763
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus-Induced Cholestatic Hepatitis in a Patient With Liver Transplant.
González-Diéguez ML; Viso Vidal D; Mendoza Pacas GE; Houghton RF
Transplantation; 2018 Oct; 102(10):e454-e456. PubMed ID: 29979348
[No Abstract] [Full Text] [Related]
12. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
14. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
[TBL] [Abstract][Full Text] [Related]
16. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
[TBL] [Abstract][Full Text] [Related]
18. [Case report of introducing MMF and steroids as an immunosuppressive therapy after living-donor liver transplantation for a patient with the diabetic nephropathy].
Kuramitsu S; Iguchi T; Ninomiya M; Yamashita Y; Harimoto N; Ikegami T; Uchiyama H; Yoshizumi T; Soejima Y; Shirabe K; Kawanaka H; Ikeda T; Furuta T; Tamada R; Maehara Y
Fukuoka Igaku Zasshi; 2014 Mar; 105(3):79-83. PubMed ID: 25000660
[TBL] [Abstract][Full Text] [Related]
19. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
Hunt SA
Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
[TBL] [Abstract][Full Text] [Related]
20. A non-induction renal sparing approach after liver transplantation: high dose mycophenolate mofetil with delayed, low-dose tacrolimus.
Rao V; Haywood S; Abecassis M; Levitsky J
Transplant Proc; 2013; 45(1):320-2. PubMed ID: 23267806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
